Valuation: Denali Therapeutics Inc.

Market Cap 2.98B 2.66B 2.46B 2.23B 4.17B 283B 4.24B 29.61B 11.72B 148B 11.19B 10.96B 468B P/E 2026 *
-8.2x
P/E 2027 * -8.09x
Enterprise Value 2.27B 2.03B 1.88B 1.7B 3.18B 216B 3.23B 22.58B 8.94B 113B 8.54B 8.35B 357B EV / Sales 2026 *
44.9x
EV / Sales 2027 * 17.1x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week+4.83%
Current month-10.69%
1 month-9.78%
3 months-21.18%
6 months-5.09%
Current year+11.81%
1 week 17.33
Extreme 17.33
19.35
1 month 17.33
Extreme 17.33
21.26
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 30/04/2022
Chief Executive Officer 50 31/07/2015
Chief Tech/Sci/R&D Officer 58 05/11/2025
Director TitleAgeSince
Director/Board Member 50 28/02/2015
Director/Board Member 73 31/03/2015
Director/Board Member 68 31/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Chief Technology Officer

-1,654 0.0010%
02/09/26 Sell

Director

-11,439 0.0072%
01/09/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%+4.83%+16.25%-1.28% 2.98B
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.38%+4.31%+26.60%+51.55% 45.81B
-1.18%+2.42%+21.92%+124.02% 43.46B
-0.39%+5.90%+252.01%+924.86% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average +0.18%+0.47%+46.01%+142.01% 38.49B
Weighted average by Cap. +0.40%+0.56%+47.44%+158.41%

Financials

2026 *2027 *
Net sales 50.65M 45.23M 41.79M 37.87M 70.84M 4.81B 72.02M 503M 199M 2.52B 190M 186M 7.94B 131M 117M 108M 97.67M 183M 12.4B 186M 1.3B 513M 6.5B 490M 480M 20.48B
Net income -445M -397M -367M -333M -622M -42.23B -632M -4.42B -1.75B -22.12B -1.67B -1.63B -69.75B -451M -403M -372M -337M -631M -42.79B -641M -4.48B -1.77B -22.42B -1.69B -1.66B -70.69B
Net Debt -708M -633M -584M -530M -991M -67.25B -1.01B -7.03B -2.78B -35.23B -2.66B -2.6B -111B -749M -669M -618M -560M -1.05B -71.07B -1.06B -7.43B -2.94B -37.24B -2.81B -2.75B -117B
Projected Income Statement - Annual - Denali Therapeutics Inc.
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
23/10/26 US$18.45 -1.15% 444,073
22/10/26 US$18.66 -0.11% 816,745
21/10/26 US$18.68 -1.32% 1,429,264
20/10/26 US$18.93 +4.93% 1,824,103
19/10/26 US$18.04 +2.44% 2,688,860
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Denali Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
18.66USD
Average target price
35.50USD
Spread / Average Target
+90.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Denali Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DNLI Stock